Ranbaxy settles patent litigation with GlaxoSmithKline

Free Trial!
Today’s Best Stocks!

Ranbaxy settles patent litigation with GlaxoSmithKline

Monday, January 21, 2008; Posted: 09:42 AM

7 Stocks You Need To Know For Tomorrow -- Free Newsletter

Jan 21, 2008 (Datamonitor via COMTEX) -- RBXLF | news | PowerRating | PR Charts -- Ranbaxy Laboratories has settled all matters relating to possible patent litigation with GlaxoSmithKline relating to sumatriptan succinate tablets, the generic version of GlaxoSmithKline's Imitrex tablets.

The terms of the settlement provide that Ranbaxy may distribute a generic version of sumatriptan succinate tablets (in the 25mg, 50mg and 100mg strengths) in the US with an expected launch date in December, 2008.

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

Morning Coffee with TradingMarkets -- Free Newsletter

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

PREMIER SPONSORED LINKS

TRADE CENTER

Please call 1-213-955-5858 ext. 1

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

RELATED SITES